A Canadian Cancer Society-funded trial shows a 3-year structured exercise program post-chemotherapy improves survival for colon cancer patients. Involving 889 participants, the trial saw a 28% ...

The Phase III trial showed that the new targeted therapy, inavolisib (Itovebi), provides significant survival benefits for ...

The new issue of ONCOLife, one of the leading oncology magazines for healthcare professionals, is now available — and it ...

Despite two decades of clinical experience with Everolimus in transplant medicine, cancer patients continue to face ...

IMUNON’s Phase 2 OVATION 2 trial of IMNN-001 in advanced ovarian cancer showed a 13-month OS increase (46 vs. 33 months) and ...

ONCOLife presents an exclusive interview with Sarah Hein, CEO of March Biosciences. In this session, we explore clinical ...

START and OneOncology are launching three new early-phase cancer trial sites in California, Texas, and New Jersey, expanding access in community settings where 70% of patients receive care.

ONCOLife presents an exclusive interview with Nick Slack, Chairman and CEO of The START Center for Cancer Research. In this session, we explore how the integration of the Carolina Urologic Research ...